Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

jesse.livermore 7 posts  |  Last Activity: Aug 10, 2015 7:42 AM Member since: Aug 21, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • jesse.livermore jesse.livermore Aug 10, 2015 7:42 AM Flag

    Are you simple?...Yes the FDA told Amarin they could not share truthful in formation with Doctors. That was why they filed a lawsuit. Might be hard for you to understand...

    ": ) JL

    Sentiment: Strong Buy

  • Reply to

    SCIENTIFIC PROBLEMS

    by money_b_gone Jul 23, 2015 3:45 AM
    jesse.livermore jesse.livermore Jul 23, 2015 7:28 AM Flag

    Variations of this post are repeated frequently on this board. There are several inaccuracies presented here, and the message is misleading because some very important fact have been ignored.

    First of all the patients were blinded to the drug they were taking...Otherwise if you knew you were in the control group, why bother taking the pills. The trial just was not "double blinded" so doctors did know what the patient was taking. As far as events are concerned there were more events in the placebo group than there were in the active (EPA) group. For example there were twice as many fatal heart attacks in the placebo group than in the EPA group. there were 36 fatal MIs in the placebo, and only 18 in the EPA group. The problem in this case and in the study as a whole was the incidence of CVD events was too low. The annual risk of an event in JELIS was only .8% in the placebo and .6% in the treated group.

    Facts are EPA lowered risk about 20% across the board. The only category where the numbers were the same was sudden. Given this was Japan, you have to wonder how many of these "sudden deaths were suicides. So EPA won every other race...The problem was the risk in all groups was so low it would have taken a population of close to 50,000 to make the numbers high enough.. As far as "unstable angina" all of you would be clinicians, who sniff at this, the reason why angina was the most impressive reduction was simply because it has the highest incidence of any of the event categories.. I would like to see some of you skeptics when you get your first bout of angina.

    JELIS did have its problems, but looking at it objectively over all it was very impressive. The risk factors in REDUCE-IT are 6-7 times higher. The improvement of the EPA/AA ratio in R-IT should be an order of magnitude higher than JELIS...Do not bet against REDUCE-IT.

    ": )jl.

  • Reply to

    Stock price movement = total fiction

    by to_the_pain Jun 23, 2015 10:35 PM
    jesse.livermore jesse.livermore Jul 3, 2015 9:09 AM Flag

    PPS = total fiction...eh?.... PPS was $.83 on Nov 10 2014. Thats up 300% in six months buckaroos. That kind of profit would have Warren Buffett dancing the Funky Chicken. Traders are "picking up pennies in front of a steam roller.

    ": ) JL

    Sentiment: Strong Buy

  • Reply to

    Short @$2.47 30,000 shares

    by optionjoe5 Jun 30, 2015 7:13 PM
    jesse.livermore jesse.livermore Jun 30, 2015 7:29 PM Flag

    What you are doing is picking up pennies in front of a road grader..

    Its you that's gonna need the luck

  • Reply to

    Excellent

    by frenzychess Jun 8, 2015 7:47 PM
    jesse.livermore jesse.livermore Jun 8, 2015 8:07 PM Flag

    Well stated....agree.

    Actually by running on so long and saying so little the FDA has managed to bring all their zany interpretations and perverted logic from the Oct 2013 AdCom into the trial. Something Amarin's stellar lawyers would have probably not been able to accomplish. FDA is a rare combination of arrogance and stupidity. They got slobber knocked by Judge Moss....

    Hello Chapter 2

    ": ) JL

    Sentiment: Strong Buy

  • Reply to

    Article about MAT9001 and Vascepa

    by onlyfactsplease Jun 3, 2015 6:11 PM
    jesse.livermore jesse.livermore Jun 5, 2015 9:52 AM Flag

    facts,...

    Please understand I do think DPA raises some serious questions about the future of w-3s as treatment for CVD and other chronic inflammatory diseases. Right now I do not know the answers to some of the questions, and am not sure the answers are known. For instance is DPA in essence (for all practical purposes) a metabolite of EPA ? Apparently DPA and EPA are inter convertible in humans. One article stated that is some interactions EPA is converted into DPA and it is DPA which is the active moiety. This raises the question of possible EPA benefits that DPA might not have . This might seem unfair, but at present the literature on EPA is vast and the literature on DPA is not vast.

    Does insuring adequate levels of EPA effectively solve the DPA deficiency problem?

    I am fascinated by your comment that MTNB can make DPA from other w-3s. Is that really true?
    Again the economies of supply are important. I guess they must be looking for the right
    algae.

    R-IT might obviate MTNB having to run an outcome trial, but that 's a big if...

    ": ) JL

  • Reply to

    Article about MAT9001 and Vascepa

    by onlyfactsplease Jun 3, 2015 6:11 PM
    jesse.livermore jesse.livermore Jun 3, 2015 9:34 PM Flag

    Dear facts...

    Suggest you stick to them...The MAT9001 story was not the lead story on the AMRN IHUB message board, That would be the FDA's actions on the First Amendment case.

    I would not get too excited about the article you cite. A standard plant to catch the suckers...Facts are...We don't even know the composition of MAT9001 so how can we come to any firm conclusion. We know it contains DPA and presumably its magic emanates from that particular N22 w-3. Even though EPA and DPA are inter convertible in humans, lets assume DPA...lowers PCSK9, lowers trigs and other non HDL_C lipid components, more than EPA, Lowers inflammation and oxidation more than EPA...the works...All things that remain unproven. This still does not necessarily make DPA a contender with EPA...We are not talking rare diseases here. In marine oils DPA averages about one tenth the amount of EPA...And don't start talking about killing the few seals that remain on the planet. To treat 10 million mixed dyslipidemia patients with 4 gms EPA requires 15% of the worlds annual production of fish oil. Currently the internet price for pure DPA is $350 for 300 mgs of DPA. The reason why MTNB's trial size was so small. I know a about the pathophysiology of w-3s in regards to lipids and CVD risk..I am not very impressed with this 28 person study over 14 days. Amarin is running a study with 7500 souls which is entering its forth year, and we still do not have enough data..

    MAT9001 has got a whole book full of questions it has to answer before it eats anyone's lunch...Maybe its you that has your head in the sand..

    ": ) JL

    Sentiment: Strong Sell

AMRN
2.12-0.09(-4.07%)Sep 1 3:59 PMEDT